Skip to content

Acute Effect of Chromatic Environment During Chemotherapy

Acute Effect of Chromatic Environment During Chemotherapy Sessions on Health Status and Pain

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03873519
Enrollment
20
Registered
2019-03-13
Start date
2018-04-15
Completion date
2020-12-15
Last updated
2020-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

chemotherapy, vital signs, stress, health status, healing environment

Brief summary

The primary objective is to examine the acute effect of color, room orientation (affecting amount of luminosity) on perceived health status and stress levels in oncologic patients during chemotherapy sessions at outpatient clinic. The secondary objectives will be to study the effect on vital signs (body temperature, heart rate, systolic blood pressure). Patients will be allocated into four conditions (Group A: Cold North, Group B: Cold South C: Warm North D: Warm South) for each session. For the next session, patients will be assigned a new condition. Assignment of sequences will be randomized for each patient. 20 patients will be randomly assigned to one of the four groups, after having signed the Free and Informed Consent Form and agreed to participate in the project, will respond to the evaluation form and will be submitted to physical examination. Patients will be treated per standard of care.

Interventions

OTHERChromatic Environment

Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.

OTHERRoom Orientation

Room will be facing North or South

Sponsors

Instituto Oncológico Balselga
CollaboratorUNKNOWN
Universidad Europea de Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Intervention model description

Patients will be allocated into four conditions (Group A: Cold North, Group B: Cold South C: Warm North D: Warm South), and they will be assigned a new condition at each next visit. The sequence will be assigned randomly to each patient. During each of the four visits, the patients will be treated per standard of care during their chemotherapy sessions. Outcome variables will be assessed before and after each visit.

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-89 years * Diagnosed with breast cancer that required chemotherapy * Followed in outpatient clinic

Exclusion criteria

* Diagnosed color blindness * Undergoing treatment with antidepressants

Design outcomes

Primary

MeasureTime frameDescription
EUROQOL-5D-5L questionnaire: EQ-VAS5 minutes before to 5 minutes after chemotherapy sessionThe EQ VAS is an independent subscale of the EUROQOL-5D-5L questionnaire, which uses a vertical visual analogue scale format. The EQ VAS is used for recording the self-rated health on a range from 0 to 100, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement
EUROQOL-5D-5L questionnaire: Self-care5 minutes before to 5 minutes after chemotherapy sessionThe patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.
EUROQOL-5D-5L questionnaire: Usual activities5 minutes before to 5 minutes after chemotherapy sessionThe patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.
EUROQOL-5D-5L questionnaire: Pain/Discomfort5 minutes before to 5 minutes after chemotherapy sessionThe patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.
EUROQOL-5D-5L questionnaire: Anxiety/Depression5 minutes before to 5 minutes after chemotherapy sessionThe patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.
EUROQOL-5D-5L questionnaire: Mobility5 minutes before to 5 minutes after chemotherapy sessionThe patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement using a 1-digit number that expresses the level selected for that dimension.

Secondary

MeasureTime frameDescription
Vital signs: body temperature5 minutes before to 5 minutes after chemotherapy sessionPer standard of care, in Celsius
Vital signs: blood pressure5 minutes before to 5 minutes after chemotherapy sessionPer standard of care, in mm Hg
Vital signs: heart rate5 minutes before to 5 minutes after chemotherapy sessionPer standard of care, in beats per minute
ID-Pain questionnaire5 minutes before to 5 minutes after chemotherapy sessionAssessment of neuropathic pain

Countries

Spain

Contacts

Primary ContactPaula Gomez Vela, BS
paulagvela@velasalvadorarquitectos.com+34620820447
Backup ContactMargarita Pérez Ruiz, MD,PhD
margarita.perez@universidadeuropea.es+34649084705

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026